首页|术后辅助化疗与同步放化疗治疗胰腺癌的临床效果探讨

术后辅助化疗与同步放化疗治疗胰腺癌的临床效果探讨

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
目的 探讨分析胰腺癌术后辅助化疗与同步放化疗的临床效果。方法 选取 88 例胰腺癌患者，通过随机数字表法进行分组，即观察组及对照组，各 44 例。对照组患者术后予以辅助化疗，观察组患者术后予以辅助化疗和同步放化疗。比较两组患者术后不同时间生存率、无病生存率、Ⅲ/Ⅳ度毒副反应发生率以及治疗前后生存质量评分。结果 观察组术后 1、2、5 年生存率分别为 75。00%、59。09%、13。64%，均高于对照组的 54。55%、36。36%、2。27%，差异显著(P<0。05)。观察组半年无病生存率、1 年无病生存率、2 年无病生存率分别为 75。00%、47。73%、31。82%，均高于对照组的 47。73%、27。27%、11。36%，差异显著(P<0。05)。对照组Ⅲ/Ⅳ度毒副反应发生率为 31。82%(14/44)，观察组Ⅲ/Ⅳ度毒副反应发生率为 11。36%(5/44)，观察组低于对照组，差异显著(χ2=5。437，P=0。020<0。05)。治疗后，两组患者生存质量中躯体疼痛、健康状况、精神状态以及生理功能评分均较治疗前提升，且观察组均高于对照组，差异显著(P<0。05)。结论 胰腺癌患者术后予以辅助化疗和同步放化疗的临床效果显著，不仅能够提升患者术后各时间生存率，同时能够让患者无病生存期和无病生存率得到提升，并能够降低毒副反应，建议临床推广应用。
Clinical effects of postoperative adjuvant chemotherapy and simultaneous chemoradiotherapy in thetreatment of pancreatic cancer
Objective To explore and analyze the clinical effects of postoperative adjuvant chemotherapy and adjuvant chemoradiotherapy in thetreatment of pancreatic cancer.Methods A total of 88 patients with pancreatic cancer were selected and divided into two groups by random number table method,namely observation group and control group,with 44 cases in each group.The control group was given adjuvant chemotherapy,and the observation group was given adjuvant chemotherapy and simultaneous chemoradiotherapy.The survival rate,disease-free survival rate,incidence of grade Ⅲ/Ⅳ toxic and side effects and quality of life score before and after treatment were compared between the two groups.Results The 1-year,2-year and 5-year survival rates in the observation group were 75.00%,59.09%and 13.64%,which were significantly higher than 54.55%,36.36%and 2.27%in the control group(P<0.05).The 6-month disease-free survival rate,1-year disease-free survival rate and 2-year disease-free survival rate in the observation group were 75.00%,47.73%and 31.82%,which were higher than 47.73%,27.27%and 11.36%in the control group,the difference was significant(P<0.05).The incidence of grade Ⅲ/Ⅳ toxic and side effects was 31.82%(14/44)in the control group and 11.36%(5/44)in the observation group;the observation group was significantly lower than the control group(χ2=5.437,P=0.020<0.05).After treatment,the scores of quality of life of physical pain,health status,mental state and physiological function in both groups were improved compared with those before treatment,and the observation group was higher than the control group,the difference was significant(P<0.05).Conclusion Postoperative adjuvant chemotherapy and concurrent chemoradiotherapy have significant clinical effects on pancreatic cancer patients,which can not only improve the postoperative survival rate of patients at all times,but also improve the disease-free survival and disease-free survival rate of patients,and reduce toxic and side effects.It is recommended to promote the clinical application.

Pancreatic cancerChemotherapyChemoradiotherapySurvival rateQuality of life

朱绪臻、谈帅

展开 >

273500 兖矿新里程总医院肿瘤三科

273500 兖矿新里程总医院肝胆外科

胰腺癌 化疗 放化疗 生存率 生存质量

2024

10.14164/j.cnki.cn11-5581/r.2024.11.028

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子：0.862
ISSN：1673-9523
年,卷(期)：2024.18(11)